Clinical trialNCT05969496RecruitingPhase 2Interventional

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

SponsorUniversity of Colorado, DenverEnrollment17Inferior Vena Cava ThrombosisKidney CancerRenal CancerRenal Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elizabeth E Kessler, MD
University of Colorado, Denver
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Colorado Cancer Center
Aurora, Colorado, United States
Corbin Eule, MDSandra Everett, FNP, MSN, RN
Recruiting
Hilands Ranch Hospital
Highlands Ranch, Colorado, United States
Elizabeth Kessler, MD
Recruiting
Lone Tree Medical Center
Lone Tree, Colorado, United States
Elizabeth Kessler, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AxitinibPembrolizumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Dec 2023
Primary completion: 1 Nov 2026
Completion: 30 Nov 2029
Last update posted: 13 Apr 2026
Registered enrollment: 17
Registry id: NCT05969496

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.